NVE (NVEC) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
3 Feb, 2026Executive summary
Revenue for Q3 FY2026 increased 23% year-over-year to $6.22 million, driven by 16% growth in product sales and a 335% surge in contract R&D revenue, with broad-based growth across defense, non-defense, distributor, and direct channels.
Net income for Q3 FY2026 rose 11% year-over-year to $3.38 million, or $0.70 per diluted share, up from $3.05 million in the prior-year quarter.
For the first nine months of FY2026, revenue grew 0.4% to $18.7 million, with net income declining 8% to $10.3 million, or $2.12 per diluted share.
Operating margin was 60%, pre-tax margin 68%, and net margin 54% for Q3 FY2026.
Financial highlights
Quarterly gross margin declined to 79% from 84% due to less profitable product mix and higher distributor sales.
Operating expenses fell 12% year-over-year, with R&D down 9% and SG&A down 19%.
Quarterly gross profit increased to $4.89 million from $4.27 million year-over-year.
Interest income decreased 3% due to a smaller marketable securities portfolio; other income dropped by $135,000.
Cash and cash equivalents at quarter-end were $3.41 million, down from $8.04 million at March 31, 2025.
Outlook and guidance
Full-year tax rate expected at 16%-17% for FY2026, aided by $700,000–$1 million in advanced manufacturing investment tax credits.
Accelerated R&D expense deductions expected to reduce cash taxes by $1.1 million for FY2026.
Optimism for a return to more normal flow in defense business and future sales from R&D investments.
Dividends to be funded through operating cash flow and maturing securities; future dividends subject to board approval and business conditions.
Latest events from NVE
- Revenue and net income declined, but gross margin and cash returns to shareholders remained strong.NVEC
Q1 20253 Feb 2026 - Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVEC
Q2 202519 Jan 2026 - Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVEC
Q3 20259 Jan 2026 - Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVEC
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, approve pay, and ratify auditor, with focus on ESG and governance.NVEC
Proxy Filing1 Dec 2025 - Key votes on directors, executive pay, and auditor ratification, with strong governance and ESG focus.NVEC
Proxy Filing1 Dec 2025 - Annual Meeting to vote on directors, executive pay, and auditor ratification August 1, 2024.NVEC
Proxy Filing1 Dec 2025 - Shareholders receive updated proxy materials and online access for upcoming governance votes.NVEC
Proxy Filing1 Dec 2025 - Strong earnings, R&D investment, and 39% shareholder return highlight a year of innovation and growth.NVEC
Proxy Filing1 Dec 2025